ELCC 2026: Cemiplimab + Chemo Benefits STK11-Mutant Non-Squamous NSCLC

At the ELCC Congress 2026, Fred R. Hirsch, MD, PhD, FASCO, Executive Director, Center for Thoracic Oncology, Icahn School of Medicine, Mount Sinai, New York, USA, presented a molecular sub-analysis from the EMPOWER-Lung 3 study. The analysis evaluated cemiplimab plus chemotherapy versus chemotherapy in non-squamous NSCLC, independent of PD-L1 expression, highlighting the predictive value of STK11 mutations for treatment benefit.